Table 2.

Clinical and Genetic Parameters Affecting PFS and OS in Primary GBM

Parameters	No. of patients (n = 147)	PFS		OS
		Median (months)	P*	Median (months)	P*
	147	8		18
TERTp status
Mutated	92	7		16
Wild type	55	10	.015	24	.017
Sex
Female	66	9		22
Male	81	7	.047	16	.055
Age at diagnosis
<60 years	52	8		18
>60 years	95	7	.172	19	.115
Preoperative KPS
>80	84	8		21
<80	56	7	.725	15	.294
Surgery
Gross toral resection	93	11		23
Absence of gross total resection	54	4	<.001	11	<.001
Ki-67 labeling index
Low (<30%)	55	8		20
High (>30%)	68	7	.212	16	.061
CD133 expression
Low (<15%)	97	8		21
High (>15%)	47	7	.480	17	.146
MGMT
Methylated	57	13		24
Unmethylated	90	7	.037	16	.015
PDGFR
Amp/gain	19	10		17
Retain	120	8	.916	20	.669
EGFR
Amp/gain	92	7		17
Retain	47	10	.060	24	.142
CDKN2A
Deletion	84	9		17
Retain	55	8	.522	21	.350
PTEN
Deletion	72	9		19
Retain	67	8	.281	19	.497
CDK4
Amp/gain	22	19		34
Retain	117	7	.015	18	.042
MDM2
Amp/gain	21	10		24
Retain	118	8	.795	18	.368
NFKBIA
Deletion	20	13		21
Retain	119	8	.802	18	.662
TP53
Mut/deletion	68	10		19
Wild type	76	7	.054	19	.580
SVZ
Positive	66	7		16
Negative	74	8	.952	21	.267
Numbers of lesion
Multifocal/distant lesions	66	7		16
Local lesion	81	9	.006	23	.001
Cohort site
Yamagata	88	7		17
Tohoku	59	9	.137	22	.107

SVZ, subventricular zone. P values <0.05 are in bold.

*Log-rank test.